Buy the Immunology-Led Pullback: AbbVie at a Tactical Entry Near $215
AbbVie's recent pullback after the 02/04/2026 quarter is a buying opportunity for a mid-term trade. Strong growth in Skyrizi and Rinvoq offset Humira's decline and produced 10% reported sales growth in Q4 2025; the market sold the stock on concerns about Humira erosion and aesthetics. Valuation is full but not frothy for a cash-generative pharma wi…